Stability of oxaliplatin in chloride-containing carrier solutions used in hyperthermic intraperitoneal chemotherapy

Mehta, Akash; Hoven, Jolanda M. van den; Rosing, Hilde; Hillebrand, M. J. X.; Nuijen, Bastiaan; Huitema, Alwin D. R.; Beijnen, Jos H.; Verwaal, Victor J.

doi:10.1016/j.ijpharm.2014.12.025

Cited by 58 publications

(44 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Specifically, oxaliplatin is a organoplatinum compound with significant activity against advanced or metastatic digestive tumors, mainly colorectal ones [8] . Therefore, oxaliplatin is considered one of the first-line drugs in the treatment of advanced colorectal cancer [9][10][11][12] . In addition, oxaliplatin does not induce nephrotoxicity to the same extent as these other platinum-based drugs [13] .…”

Section: Introductionmentioning

confidence: 99%

Influence of PLGA and PLGA-PEG on the dissolution profile of oxaliplatin

et al. 2016

View full text Add to dashboard Cite

SbstractOxaliplatin was inserted into polymeric matrices aiming to study the interaction of this drug with these polymers and its capability to diffuse to the environment. Tested polymers were: (1) polyethylene glycol (PEG), (2) poly(lactic-co-glycolic acid) (PLGA), and (3) a copolymer of them (PLGA-PEG). The latter two were synthesized by us using polycondensation in bulk. Oxaliplatin was included in the matrices by the melt mixing process followed by casting. Fourier tran sform infrared spectroscopy (FTIR), proton nuclear magnetic resonance ( 1 H-NMR) and X-ray diffraction (DRX) studies of the polymers were performed proving the obtaining of the desired materials. In addition, the interaction between drug and matrices and the release profile of the oxaliplatin from these matrices were analyzed. Among them, PEG did not control the oxaliplatin release. In turn, PLGA and PLGA-PEG present drug release profiles quite similar. Oxaliplatin was completely released from PLGA and PLGA-PEG in 5 hours, by a relaxation mechanism. There was no evidence of oxaliplatin interaction with the different polymers. In addition, as the PEG improves the biocompatibility and biomasking, obtained results prove the obtaining of a drug release system, which allowed the total use of the drug improving the cancer treatment and even the welfare of the patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Influence of PLGA and PLGA-PEG on the dissolution profile of oxaliplatin

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Similarly, as carrier solutions, we suggest the use of 1.5% dextrose isotonic peritoneal dialysis solutions for any drug protocol proposed 53 here, even for those oxaliplatin-based schedules 59,60 . Because the main risk of HIPEC is related to direct or indirect skin exposure to antiblastic drugs, the use of two pairs of gloves should be mandatory to protect the surgical team during abdomen manipulation after the "emptying phase" [61][62][63] .…”

Section: Proposal For Standardizing Procedures Patients Selectionmentioning

confidence: 99%

A proposal of Brazilian Society of Surgical Oncology (BSSO/SBCO) for standardizing cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) procedures in Brazil: pseudomixoma peritonei, appendiceal tumors and malignant peritoneal mesothelioma

Batista

Sarmento

Loureiro³

et al. 2017

Rev. Col. Bras. Cir.

View full text Add to dashboard Cite

Cytoreductive surgery plus hypertermic intraperitoneal chemotherapy has emerged as a major comprehensive treatment of peritoneal malignancies and is currently the standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome as well as malignant peritoneal mesothelioma. Unfortunately, there are some worldwide variations of the cytoreductive surgery and hypertermic intraperitoneal chemotherapy techniques since no single technique has so far demonstrated its superiority over the others. Therefore, standardization of practices might enhance better comparisons between outcomes. In these settings, the Brazilian Society of Surgical Oncology considered it important to present a proposal for standardizing cytoreductive surgery plus hypertermic intraperitoneal chemotherapy procedures in Brazil, with a special focus on producing homogeneous data for the developing Brazilian register for peritoneal surface malignancies.

show abstract

“…However, in a recent in vitro study, the usage of carrier solutions containing chloride for oxaliplatin did not significantly affect its concentrations (<10 % degradation after 30 min as well as <20 % degradation after 120 min at a temperature of 42°C) [80]. Chloride probably promotes the formation of the active cytotoxic form of oxaliplatin and consequently could even enhance its cytotoxic effect.…”

Section: Oxaliplatinmentioning

confidence: 87%

“…Because oxaliplatin is unstable in solutions containing chloride, it has been diluted in a dextrose 5 % solution, which has given rise to serious electrolyte disturbances and hyperglycaemia during and after intraperitoneal chemotherapy, especially at higher temperatures [79,80]. However, in a recent in vitro study, the usage of carrier solutions containing chloride for oxaliplatin did not significantly affect its concentrations (<10 % degradation after 30 min as well as <20 % degradation after 120 min at a temperature of 42°C) [80].…”

Section: Oxaliplatinmentioning

confidence: 99%

Pharmacological principles of intraperitoneal and bidirectional chemotherapy

Bree

Michelakis

Stamatiou

et al. 2017

Pleura and Peritoneum

View full text Add to dashboard Cite

Intraperitoneal chemotherapy is associated with a significant pharmacokinetic and pharmacodynamic benefit and can, alone or in combination with systemic chemotherapy (bidirectional chemotherapy), be used for treating primary and secondary peritoneal surface malignancies. Due to the peritoneal-plasma barrier, high intraperitoneal drug concentration can be achieved by intraperitoneal chemotherapy, whereas systemic concentration remains low. Bidirectional chemotherapy may provide in addition adequate drug concentrations from the side of the subperitoneal space to the peritoneal tumour nodules. Major pharmacological problems of intraperitoneal chemotherapy are limited tissue penetration and poor homogeneity of drug distribution to the entire seroperitoneal surface. Significant pharmacological determinants of intraperitoneal chemotherapy are choice of drug, drug dosage, solution volume, carrier solution, intra-abdominal pressure, temperature, duration, mode of administration, extent of peritonectomy and interindividual variability. Drugs most commonly applied for intraperitoneal chemotherapy include mitomycin C, cisplatin, carboplatin, oxaliplatin, irinotecan, 5-fluoruracil, gemcitabine, paclitaxel, docetaxel, doxorubicin, premetrexed and melphalan. The drugs and their doses that are used vary widely among centres. While the adequate drug choice for intraperitoneal and bidirectional chemotherapy is essential, randomized clinical trials to determine the most optimal drug or drug combination are lacking, and only eight retrospective comparative clinical studies are available. Further clinical pharmacological studies are required to determine the most effective drug regimen for intraperitoneal and bidirectional chemotherapy in various indications. In the future, reliable drug sensitivity testing and genetic profiling of peritoneal metastases will be needed for enabling patient-specific therapy.

show abstract

Stability of oxaliplatin in chloride-containing carrier solutions used in hyperthermic intraperitoneal chemotherapy

Cited by 58 publications

References 17 publications

Influence of PLGA and PLGA-PEG on the dissolution profile of oxaliplatin

Influence of PLGA and PLGA-PEG on the dissolution profile of oxaliplatin

A proposal of Brazilian Society of Surgical Oncology (BSSO/SBCO) for standardizing cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) procedures in Brazil: pseudomixoma peritonei, appendiceal tumors and malignant peritoneal mesothelioma

Pharmacological principles of intraperitoneal and bidirectional chemotherapy

Contact Info

Product

Resources

About